

**Africure Pharmaceuticals Ltd**

(Incorporated in the Republic of Mauritius)

(Registration number: C145852 C1/GBL)

Having its registered address at

6<sup>th</sup> Floor, Tower A, 1 Cybercity, Ebene, Republic of Mauritius

(“Africure” or “the Company” or the “Group”)



---

**APPROVAL TO LIST ON THE STOCK EXCHANGE OF MAURITIUS LTD**

---

The Board of Directors of Africure (the “Board”) is pleased to announce that the Listing Executive Committee of the Stock Exchange of Mauritius Ltd (the “SEM”) has approved on 29 December 2020, the listing on the Official Market of the SEM of:-

- (a) the issued 8,337,500 ordinary shares of no par value of the Company by way of introduction; and
- (b) up to an additional 2,000,000 ordinary shares of no par value of the Company through various placings which may take place subsequent to the listing on the SEM.

The 8,337,500 ordinary shares of no par value of the Company already in issue will be listed on the Official Market of the SEM on 18 January 2021. For the time being, the directors of the Company do not anticipate that an active secondary market will develop in the ordinary shares of Africure on the Official Market.

Further details of any offer, including salient dates and time, the number of ordinary shares being offered through the placing(s) and the offer price will be communicated to targeted investors and the market in due course.

The Company was incorporated on 17 March 2017 under the laws of the Republic of Mauritius and holds a Global Business Licence issued by the Financial Services Commission in accordance with the Financial Services Act 2007. The principal activity of the Company is investment holding of manufacturing assets in Sub Saharan Africa, trading & procurement of pharmaceutical products. The Group is also a manufacturer and distributor of essential pharmaceutical products for human consumption (e.g. antibiotics, anti-inflammatory, anti-diabetic, pain killers, anti-viral, anti-malaria drugs). It holds manufacturing facilities in Cameroon, Cote d’Ivoire, Tanzania, Botswana, India and distribution companies in various countries. Africure’s objective is to create manufacturing capabilities in Africa and to respond to challenges faced by the African continent with regards to its overdependence on imported pharmaceutical products.

Copies of the Listing Particulars of Africure, as required by the Listing Rules of the SEM, are available for inspection for a period of ten (10) business days as from 30 December 2020, during normal office hours (from 09:00 to 17:00 Mauritian time) at the registered office of the Company which is situated at 6<sup>th</sup> Floor, Tower A, 1 Cybercity, Ebene, Republic of Mauritius.

This announcement is not an invitation to the public to subscribe for ordinary shares in the Company and is provided for information purposes only.

By order of the Board

30 December 2020

---

*This notice is issued pursuant to SEM Listing Rules 10.4 and 11.3. The Board of Directors of Africure accepts full responsibility for the accuracy of the information contained in this Communiqué.*

For further information please contact:

**Mauritian Transaction Advisor and SEM Authorised  
Representative & Sponsor**



+230 402 0890

**Company Secretary**



+230 403 6000